THERAVANCE BIOPHARMA INC. overview

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results PR Newswire DUBLIN, Feb. 26, 2025 YUPELRI ® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion , up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study...

Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, Feb. 20, 2025 DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45 th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST ( 8:50 am PST / 4:50 pm GMT ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under the Investors section,...

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 PR Newswire DUBLIN, Ireland, Feb. 12, 2025 DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST ( 2:00 pm PST / 10:00 pm...

Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, Feb. 5, 2025 DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST ( 9:00 am PST / 5:00 pm GMT ). Webcast of the event may be accessed by visiting Theravance.com , under the Investors section, Events and Presentations. Replay of the webcast will be archived on...

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference PR Newswire DUBLIN, Dec. 17, 2024 DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025 , in San Francisco, CA. To request a one-on-one meeting with the Theravance...

Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, Nov. 20, 2024 DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7 th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST ( 8:15 am PST / 4:15 pm GMT ) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com , under...

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value PR Newswire DUBLIN, Nov. 12, 2024 Third quarter results highlight strong operational performance across key value drivers: YUPELRI ® (revefenacin) net sales of $62.2 million , recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 1 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%,...

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 PR Newswire DUBLIN, Oct. 24, 2024 DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024 . An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST ( 2:00 pm PST / 10:00 pm GMT ) that day. Conference Call Information To...